MK0524B Bioequivalence Study (0524B-070)

NCT00943124 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia

Interventions

DRUG: MK0524B (ER niacin (+) laropiprant (+) simvastatin)
DRUG: MK0524A (ER niacin + laropiprant)
DRUG: Simvastatin

Sponsor

Merck Sharp & Dohme LLC